process and analytical development

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. Its lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage clinical development for Duchenne muscular dystrophy (DMD). Capricor also leverages its proprietary StealthX™ exosome platform focused on vaccinology and targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics.

Read more

allogeneic cardiosphere-derived cells (CDCs)cell and exosome-based biologyclinical developmentexosome engineeringmanufacturing

Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cellular therapy market. It was the first company to successfully develop and commercialize an immunotherapy made from a patient's own cells, gaining FDA approval for PROVENGE (sipuleucel-T) in 2010, which has been prescribed to nearly 40,000 men with advanced prostate cancer.

Read more

apheresis managementautologous and allogeneic cell therapy manufacturingcell-based potency assayscellular therapy manufacturingcGMP manufacturingclinical and regulatory supportendotoxin testingFlow Cytometrylogistics and delivery of time-critical therapiesPCRquality control testing